1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market : Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies

Key Findings

• The number of MS prevalent cases globally (10 Million) is predicted to increase from in 2013 to by 2023.
• The United States MS market is entering a new phase of growth that is driven by the development of innovative therapeutic platforms.
• Recent therapeutics advances focus on a couple of factors:
o Improving tolerability of existing products specifically for interferon beta and glatiramer acetate
o Development of anti-inflammatory medications
o More clinical studies done investigating treatments in progressive MS
o Many clinical studies now include effects of Vitamin D in relapsing MS
• The existing interferon therapies—Avonex, Rebif, Betaseron/Extavia, and Plegridy, along with novel therapies such as Copaxone, Tysabri, Novantrone, Gilenya, and Tecfidera—have helped build a patient base in a market that has a very high degree of unmet medical needs.
• Oral therapies are revolutionizing the treatment paradigm of MS by improving dosing and patient compliance. Biogen’s Tecfidera, in particular, has been a game changer in the US MS market, stealing shares from older therapies.
• Newer treatments have the potential to treat refractory MS patients as well as patients suffering from primary progressive MS (PPMS).
• There is significant interest from big pharmaceutical, biotechnology, and specialty pharmaceutical companies to enter or expand their position within the market.

Methodology and Scope

• This research service focuses on prescription drugs used to treat MS.
• A product and pipeline assessment is provided for marketed and investigational drugs for the treatment of MS. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
• The information contained in this research service was derived from published sources, including disease organization Web sites; public health organization Web sites; company publications including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

Table Of Contents

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market : Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies
Executive Summary 4
• Recent Market Developments 6
• Defining Healthcare Trends in the Future 8
• Companies to Watch 10
Methodology and Scope 11
Introduction 13
• Market Overview—Segmentation 15
Market Background 18
• Prevalence of Multiple Sclerosis in Major Markets 19
• Physician Guideline to Multiple Sclerosis Therapy 21
Competitive Landscape 22
Profiles of Launched and Late Stage Investigational Products 42
Conclusions and Recommendations 58
The Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Global Salicylic Acid Market

  • January 2017
    16 pages
  • Salicylic Acid  

  • World  

View report >

Cancer Statistics in Denmark

  • January 2017
    6 pages
  • Therapy  

  • Denmark  

View report >

Anti-Infective Market in India

  • January 2017
    4 pages
  • Anti-Infective  

    Blood Disease  

  • India  

    United States  

View report >

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.